AGIO - Agios Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$42.00
DETAILS
HIGH:
$50.00
LOW:
$36.00
MEDIAN:
$40.00
CONSENSUS:
$42.00
UPSIDE:
49.25%
About Agios Pharmaceuticals, Inc. (https://www.agios.com)
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Brian Goff | Chief Executive Officer & Director | 1969 | $1,451,457 USD |
| Krishnan Viswanadhan | Chief Corporate Development & Strategy Officer | 1979 | $931,509 USD |
| Sarah Gheuens | Chief Medical Officer and Head of Research & Development | 1980 | $887,232 USD |
| Tsveta Milanova | Chief Commercial Officer | 1978 | $836,643 USD |
| Cecilia Jones | Chief Financial Officer | 1975 | $791,835 USD |
| James William Burns | Chief Legal Officer | 1978 | $780,510 USD |
| Craig Thompson | Co-Founder | 1953 | $50,000 USD |
| Lewis Clayton Cantley | Co-Founder | 1949 | $50,000 USD |
| Shin-San Su | Co-Founder | 1956 | $50,000 USD |
| Tak Wah Mak FRSC | Co-Founder | 1946 | $50,000 USD |
| Clive Patience | Chief Technical Operations Officer | 1964 | – |
| Steven Vickers | Vice President of Sales | – | – |
| T. J. Washburn | Vice President, Controller & Principal Accounting Officer | 1982 | – |